Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
暂无分享,去创建一个
U. Studer | M. Fey | G. Thalmann | E. Karamitopoulou-Diamantis | A. Vidal | Á. Vidal | M. F. Fey | G. Thalmann | A. Vidal | U. E. Studer | E. Karamitopoulou-Diamantis
[1] O. Ståhl,et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] S. Fosså,et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Fosså,et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Guimarães,et al. Bilateral testicular germ cell tumours: a systematic review , 2012, BJU international.
[5] J. Boone,et al. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors , 2011, Cancer.
[6] S. Fosså,et al. Sequelae of treatment in long-term survivors of testis cancer. , 2011, European urology.
[7] A. Horwich,et al. EAU guidelines on testicular cancer: 2011 update. , 2011, European urology.
[8] M. Dimopoulos,et al. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. , 2011, Urologic oncology.
[9] S. Fosså,et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Gleave,et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] S. Fosså,et al. Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors , 2009, Journal of the National Cancer Institute.
[12] U. Studer,et al. High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy , 2009, World Journal of Urology.
[13] R. Bremnes,et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Warde,et al. A comprehensive systematic review of testicular germ cell tumor surveillance. , 2007, Critical reviews in oncology/hematology.
[15] D. Dearnaley,et al. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy , 2006, BJU international.
[16] J. Bacik,et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Bachaud,et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. , 2004, European urology.
[18] M. Williams,et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. , 2004, Urology.
[19] J. Habbema,et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Fimmers,et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Sweeney,et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. , 2000, The Journal of urology.
[22] D. Böhlen,et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. , 1999, The Journal of urology.
[23] D. Carter. TNM Classification of Malignant Tumors , 1998 .
[24] M. Williams,et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Pont,et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] U. Studer,et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. , 2008, The Journal of urology.
[27] I. Sesterhenn,et al. Histological Classification of Testis Tumours , 1998 .